TrialEuropean journal of cancer (Oxford, England : 1990)2024

Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.

Pasquale Rescigno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.